Author:
Handelsman Yehuda,Henry Robert R.,Bloomgarden Zachary T.,Dagogo-Jack Sam,DeFronzo Ralph A.,Einhorn Daniel,Ferrannini Ele,Fonseca Vivian A.,Garber Alan J.,Grunberger George,LeRoith Derek,Umpierrez Guillermo E.,Weir Matthew R.
Subject
Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism
Reference51 articles.
1. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood;U.S. Food and Drug Administration,2015
2. NCHS National Hospital Discharge Survey;Centers for Disease Control and Prevention,2010
3. Diabetic ketoacidosis and related events in the Canagliflozin Type 2 Diabetes Clinical Program;Erondu;Diabetes Care,2015
4. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015
5. Efficacy and safety of canagliflozin, a sodium glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes;Henry;Diabetes Care,2015
Cited by
261 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献